The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Subscribe To Our Newsletter & Stay Updated
